Email ID
Password
Sign me in automatically next time
Business
EVENTS
04 April 2016
Stockholm, Sweden
06 April 2016
Hamburg, Germany
JOB OF THE WEEK Promote your job vacancy
Could Eli Lilly & Co.'s CDK 4/6 inhibitor abemaciclib beat Novartis AG's offering to market and trespass on Pfizer Inc.'s Ibrance (palbociclib) sales more than a year earlier than anticipated? In its fourth quarter earnings call, Lilly surprised investors by suggesting it would consider filing abemaciclib as a treatment for breast cancer on the back of Phase II data from its MONARCH-1 study, due to read out by mid-year 2016. Interim data for the drug is expected sooner. Dr. Susan Mahony, ...
 
A regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription ...
Gilead Sciences has moved court to block an alleged copy of its blockbuster hepatitis C treatment, Harvoni (sofosbuvir/ledipasvir), in India which it believes not only wrongly rides on the brand name but may also not have the requisite regulatory approvals. Gilead said that it discovered Bombay ...
 
Pfizer Inc. 's pending $160bn merger with Allergan PLC may be its best shot at significant revenue growth this year, since the company's 2015 revenue and earnings fell below 2014 totals due to foreign currency impacts and the loss of patent exclusivity for multiple products – factors that again ...
Informa Pharma's Global Director of Content Mike Ward and Scrip Intelligence West Coast Editor Mandy Jackson moderated a roundtable discussion on Jan. 11, the opening day of the 34th Annual J.P. Morgan Healthcare Conference, in San Francisco during which they spoke with eight biotechnology veterans ...
 
One of the most frightening experiences I had as an infantry soldier was to come under, albeit simulated, mortar fire. Sitting in a damp ditch at night whilst the enemy threw what would have been high explosive and shrapnel at me gave me nightmares for weeks afterwards. In a very metaphorical ...
Torrent Pharmaceuticals reported a strong set of numbers for the third quarter ended December 2015, despite turbulence in markets like Brazil, where it has done some sharp "belt tightening", and remains "bullish" long term. Torrent reported revenues of INR15.39bn ($228m), an increase of 32%, and ...
 
Merck & Co. Inc. urged investors to basically look past a flat fourth quarter 2015 performance on Feb. 3, emphasizing the promise of its cancer immunotherapy Keytruda (pembrolizumab) and its just-approved hepatitis C combo Zepatier (elbasvir/grazoprevir) to begin to offset revenue losses elsewhere ...
Pfizer Inc. 's pending $160bn merger with Allergan PLC may be its best shot at significant revenue growth this year, since the company's 2015 revenue and earnings fell below 2014 totals due to foreign currency impacts and the loss of patent exclusivity for multiple products – factors that again ...
 
The 180-day notice of commercial marketing for biosimilars is a "standalone" measure in the Biologics Price Competition and Innovation Act of 2009 (BPCIA) and there's nothing in the law or in a ruling last summer from an appeals court that "conditions" the provision on any other part of the ...
Gilead Sciences has moved court to block an alleged copy of its blockbuster hepatitis C treatment, Harvoni (sofosbuvir/ledipasvir), in India which it believes not only wrongly rides on the brand name but may also not have the requisite regulatory approvals. Gilead said that it discovered Bombay ...
 

Editorial: Put Robots In The C-Suite!
13 January 2016
Eleanor Malone

© 2016 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36